192 related articles for article (PubMed ID: 16483344)
1. Selective renal arterial infusion of fenoldopam for the prevention of contrast-induced nephropathy.
Ng MK; Tremmel J; Fitzgerald PJ; Fearon WF
J Interv Cardiol; 2006 Feb; 19(1):75-9. PubMed ID: 16483344
[TBL] [Abstract][Full Text] [Related]
2. Contrast-induced nephropathy: protective role of fenoldopam.
Caixeta A; Dogan O; Weisz G
Clin Exp Pharmacol Physiol; 2012 Jun; 39(6):497-505. PubMed ID: 22642656
[TBL] [Abstract][Full Text] [Related]
3. Design and rationale of CONTRAST--a prospective, randomized, placebo-controlled trial of fenoldopam mesylate for the prevention of radiocontrast nephropathy.
Stone GW; Tumlin JA; Madyoon H; Lepor NE; McCullough PA; Mathur VS; Murray PT; O'Neill WW
Rev Cardiovasc Med; 2001; 2 Suppl 1():S31-6. PubMed ID: 12439366
[TBL] [Abstract][Full Text] [Related]
4. Differential effects between intravenous and targeted renal delivery of fenoldopam on renal function and blood pressure in patients undergoing cardiac catheterization.
Teirstein PS; Price MJ; Mathur VS; Madyoon H; Sawhney N; Baim DS
Am J Cardiol; 2006 Apr; 97(7):1076-81. PubMed ID: 16563920
[TBL] [Abstract][Full Text] [Related]
5. Direct infusion of fenoldopam into the renal arteries to protect against contrast-induced nephropathy in patients at increased risk.
Talati S; Kirtane AJ; Hassanin A; Mehran R; Leon MB; Moses JW; Weisz G
Clin Exp Pharmacol Physiol; 2012 Jun; 39(6):506-9. PubMed ID: 22469256
[TBL] [Abstract][Full Text] [Related]
6. Use of fenoldopam to prevent radiocontrast nephropathy in high-risk patients.
Madyoon H; Croushore L; Weaver D; Mathur V
Catheter Cardiovasc Interv; 2001 Jul; 53(3):341-5. PubMed ID: 11458411
[TBL] [Abstract][Full Text] [Related]
7. Dopamine-1 receptor agonist: renal effects and its potential role in the management of radiocontrast-induced nephropathy.
Asif A; Epstein DL; Epstein M
J Clin Pharmacol; 2004 Dec; 44(12):1342-51. PubMed ID: 15545304
[TBL] [Abstract][Full Text] [Related]
8. First experience with intra-renal fenoldopam in a patient with heart failure.
Cohen MG
J Invasive Cardiol; 2005 May; 17(5):274-6. PubMed ID: 15879609
[No Abstract] [Full Text] [Related]
9. Contrast-induced nephropathy.
Pucelikova T; Dangas G; Mehran R
Catheter Cardiovasc Interv; 2008 Jan; 71(1):62-72. PubMed ID: 17975790
[TBL] [Abstract][Full Text] [Related]
10. Impaired blood flow in acute kidney injury: pathophysiology and potential efficacy of intrarenal vasodilator therapy.
Tumlin JA
Curr Opin Crit Care; 2009 Dec; 15(6):514-9. PubMed ID: 19829105
[TBL] [Abstract][Full Text] [Related]
11. Multifactorial acute renal failure treated with percutaneous targeted renal therapy (TRT): a case of "dialysis rescue".
Allie DE; Hebert CJ; Walker CM
J Invasive Cardiol; 2007 Feb; 19(2):E27-30. PubMed ID: 17268046
[No Abstract] [Full Text] [Related]
12. Fenoldopam prophylaxis of postoperative acute renal failure in high-risk cardiac surgery patients.
Ranucci M; Soro G; Barzaghi N; Locatelli A; Giordano G; Vavassori A; Manzato A; Melchiorri C; Bove T; Juliano G; Uslenghi MF
Ann Thorac Surg; 2004 Oct; 78(4):1332-7; discussion 1337-8. PubMed ID: 15464494
[TBL] [Abstract][Full Text] [Related]
13. Safety and performance of targeted renal therapy: the Be-RITe! Registry.
Weisz G; Filby SJ; Cohen MG; Allie DE; Weinstock BS; Kyriazis D; Walker CM; Moses JW; Danna P; Fearon WF; Sachdev N; Wiechmann BN; Vora K; Findeiss L; Price MJ; Mehran R; Leon MB; Teirstein PS
J Endovasc Ther; 2009 Feb; 16(1):1-12. PubMed ID: 19281283
[TBL] [Abstract][Full Text] [Related]
14. Comparison of N-acetylcysteine and fenoldopam for preventing contrast-induced nephropathy (CAFCIN).
Ng TM; Shurmur SW; Silver M; Nissen LR; O'Leary EL; Rigmaiden RS; Cieciorka M; Porter LL; Ineck BA; Kline ME; Puumala SE
Int J Cardiol; 2006 May; 109(3):322-8. PubMed ID: 16039733
[TBL] [Abstract][Full Text] [Related]
15. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial.
Stone GW; McCullough PA; Tumlin JA; Lepor NE; Madyoon H; Murray P; Wang A; Chu AA; Schaer GL; Stevens M; Wilensky RL; O'Neill WW;
JAMA; 2003 Nov; 290(17):2284-91. PubMed ID: 14600187
[TBL] [Abstract][Full Text] [Related]
16. Contrast-induced nephropathy: a review.
Sanaei-Ardekani M; Movahed MR; Movafagh S; Ghahramani N
Cardiovasc Revasc Med; 2005; 6(2):82-8. PubMed ID: 16263365
[TBL] [Abstract][Full Text] [Related]
17. Targeted renal therapy and contrast-induced nephropathy during endovascular abdominal aortic aneurysm repair: results of a feasibility pilot trial.
Allie DE; Lirtzman MD; Wyatt CH; Keller VA; Mitran EV; Hebert CJ; Patlola R; Veerina KK; Walker CM
J Endovasc Ther; 2007 Aug; 14(4):520-7. PubMed ID: 17696627
[TBL] [Abstract][Full Text] [Related]
18. Acetylcysteine and fenoldopam. Promising new approaches for preventing effects of contrast nephrotoxicity.
Thompson EJ; King SL
Crit Care Nurse; 2003 Jun; 23(3):39-46. PubMed ID: 12830779
[TBL] [Abstract][Full Text] [Related]
19. Contrast agent--associated nephrotoxicity.
Briguori C; Tavano D; Colombo A
Prog Cardiovasc Dis; 2003; 45(6):493-503. PubMed ID: 12800130
[TBL] [Abstract][Full Text] [Related]
20. Radiocontrast-induced acute renal failure: allocations and outcomes.
Mehran R; Ashby DT
Rev Cardiovasc Med; 2001; 2 Suppl 1():S9-13. PubMed ID: 12439362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
